Lamivudine monotherapy as a holding regimen in the era of antiretroviral treatment resistance

Johanna Catharina Meyer; Natalie Schellack

Lamivudine monotherapy as a holding regimen in the era of antiretroviral treatment resistance

Johanna Catharina Meyer^*, Natalie Schellack

^*Corresponding author for this work

Research output: Contribution to journal › Literature review › peer-review

Abstract

© Medpharm. Limited treatment options are available for HIV-infected paediatric patients that are virologically failing combination antiretroviral treatment (cART). This paper describes the use of lamivudine monotherapy (LM) as a holding strategy for the short-term treatment of specific multi-drug resistant paediatric patients, where a definite suppressive cART regimen is not possible. Lamivudine monotherapy should only be used under close supervision and monitoring of an expert HIV clinician.

Original language	English
Pages (from-to)	43-45
Number of pages	3
Journal	SA Pharmaceutical Journal
Volume	82
Issue number	9
Publication status	Published - 1 Jan 2015

Keywords

Holding regimen
Lamivudine monotherapy
Paediatric ART
Virological failure

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{7c5ea21d8e1f46a0b81d0ea521da1a3c,

title = "Lamivudine monotherapy as a holding regimen in the era of antiretroviral treatment resistance",

abstract = "{\textcopyright} Medpharm. Limited treatment options are available for HIV-infected paediatric patients that are virologically failing combination antiretroviral treatment (cART). This paper describes the use of lamivudine monotherapy (LM) as a holding strategy for the short-term treatment of specific multi-drug resistant paediatric patients, where a definite suppressive cART regimen is not possible. Lamivudine monotherapy should only be used under close supervision and monitoring of an expert HIV clinician.",

keywords = "Holding regimen, Lamivudine monotherapy, Paediatric ART, Virological failure",

author = "Meyer, {Johanna Catharina} and Natalie Schellack",

year = "2015",

month = jan,

day = "1",

language = "English",

volume = "82",

pages = "43--45",

journal = "SA Pharmaceutical Journal",

issn = "1015-1362",

publisher = "Medpharm Publications",

number = "9",

}

TY - JOUR

T1 - Lamivudine monotherapy as a holding regimen in the era of antiretroviral treatment resistance

AU - Meyer, Johanna Catharina

AU - Schellack, Natalie

PY - 2015/1/1

Y1 - 2015/1/1

N2 - © Medpharm. Limited treatment options are available for HIV-infected paediatric patients that are virologically failing combination antiretroviral treatment (cART). This paper describes the use of lamivudine monotherapy (LM) as a holding strategy for the short-term treatment of specific multi-drug resistant paediatric patients, where a definite suppressive cART regimen is not possible. Lamivudine monotherapy should only be used under close supervision and monitoring of an expert HIV clinician.

AB - © Medpharm. Limited treatment options are available for HIV-infected paediatric patients that are virologically failing combination antiretroviral treatment (cART). This paper describes the use of lamivudine monotherapy (LM) as a holding strategy for the short-term treatment of specific multi-drug resistant paediatric patients, where a definite suppressive cART regimen is not possible. Lamivudine monotherapy should only be used under close supervision and monitoring of an expert HIV clinician.

KW - Holding regimen

KW - Lamivudine monotherapy

KW - Paediatric ART

KW - Virological failure

UR - http://www.scopus.com/inward/record.url?scp=84947208318&partnerID=8YFLogxK

M3 - Literature review

SN - 1015-1362

VL - 82

SP - 43

EP - 45

JO - SA Pharmaceutical Journal

JF - SA Pharmaceutical Journal

IS - 9

ER -

Lamivudine monotherapy as a holding regimen in the era of antiretroviral treatment resistance

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this